Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial

A. M. Morelli, M. R. Migliorino, A. Morabito, R. Chiari, F. Grossi, P. Bordi, F. Di Costanzo, A. Delmonte, G. Romano, A. Misino, V. Scotti, V. Gregorc, S. Pisconti, G. L. Ceresoli, A. Del Conte, I. Colantonio, L. Ciuffreda, E. Capelletto, I. Stura, S. Novello

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)viii506-viii507
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Publication statusPublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this